NEWS RELEASE

RECORDATI: TAX PETITION FOR THE FRUITION OF ACE TAX BENEFITS DERIVING FROM THE REVERSE MERGER OBTAINED POSITIVE ANSWER

Milan, 9 December 2020 – On 1st October 2020, Recordati announced that the Boards of Directors of Rossini Investimenti S.p.A., Fimei S.p.A. and Recordati S.p.A. - all subject to the management and coordination activity of Rossini Luxembourg S.à r.l. – had examined and had approved the reverse merger by incorporation of Rossini Investimenti and Fimei into Recordati (the “Merger”) and the documentation preparatory to implementation of the Merger, planned to be completed during the first half of 2021.

As a result of the Merger and subject to tax ruling, Recordati will be able to enjoy the ACE tax benefits generated by Rossini Investimenti, as described in greater detail in the Merger Plan and in the Information Document, made available to the public on the Company’s website, as already communicated. In this respect, please note that the tax petition has obtained a positive answer from the Italian Internal Revenue Agency.

The completion of the Merger is conditional upon approval by the extraordinary shareholders’ meeting called on 17 December 2020.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: investorrelations@recordati.it

Media Relations
Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.